What is the current market size?

The Aurora Kinase B Protein market size was valued at USD 1.2 billion in 2023, driven by oncology research advancements and therapeutic development.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by targeted cancer therapies and biotechnology innovations.

What are the primary growth drivers?

Key drivers include rising cancer incidence, increased investment in kinase inhibitor research, and advancements in precision medicine technologies.

What challenges does the market face?

High R&D costs, stringent regulatory requirements, and limited awareness of Aurora Kinase B's role in disease mechanisms hinder market growth.

Which regions are market leaders?

North America leads with 40% market share, followed by Europe, due to advanced biotech infrastructure and strong pharmaceutical R&D ecosystems.

Who are the top companies in the market?

Key players include Merck KGaA, Thermo Fisher Scientific, Abcam, and Cell Signaling Technology, focusing on product differentiation and strategic collaborations.

What opportunities exist in the future?

Emerging opportunities include expanding applications in rare diseases, AI-driven drug discovery, and growing demand for personalized cancer therapies.

How is technology impacting the market?

Next-gen sequencing, CRISPR-based tools, and machine learning are accelerating drug development and improving Aurora Kinase B target validation.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA prioritize safety and efficacy, with streamlined pathways for fast-tracked oncology therapies boosting market compliance.

Aurora Kinase B Protein Market Metrics & Forecast Analysis 2033

Aurora Kinase B Protein by Application (Hospital, Research Institute, Others), by Types (AZD-2811, CS-2164, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Aurora Kinase B Protein Market Overview

The Aurora Kinase B Protein market represents a specialized segment of the oncology therapeutic landscape, targeting the development of inhibitors and research tools for cancer treatment and diagnostics. As a critical regulator of cell division, Aurora Kinase B has emerged as a high-priority therapeutic target, driving innovation in personalized medicine and precision oncology. The Aurora Kinase B Protein market size was estimated at $150 million in 2025, with a growth outlook projected to accelerate through 2033. The market forecast highlights strategic industry expansion driven by advancements in targeted therapies, rising demand for biomarker-driven drug development, and increased R&D investments in cancer research.

Loading chart…

The Aurora Kinase B Protein market is anticipated to grow at a compound annual growth rate (CAGR) of 13.5% through 2033, propelled by macro drivers such as the rising incidence of hematological cancers and technological breakthroughs in AI-driven drug discovery. Key industry forces shaping the market include regulatory incentives for orphan drug approvals, collaborations between biotech firms and academic institutions, and supply-chain optimizations for protein-based therapeutics. North America remains the largest market due to established biopharma infrastructure, while Asia-Pacific is the fastest-growing region, fueled by expanding healthcare access and government-funded oncology initiatives. Strategic partnerships and patent expirations of first-generation inhibitors are expected to intensify competitive dynamics, creating opportunities for niche players to enter the space.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	379.43 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sino Biological, Inc.; Thermo Fisher Scientific (China) Co.,Ltd.; Elabscience Biotechnology Inc.; OriGene Technologies, Inc.; Cielo Therapeutics Inc; Sanofi; AbbVie Inc.; Advenchen Laboratories LLC; Aeterna Zentaris Inc.; Amgen Inc.; AstraZeneca Plc.; Chipscreen Biosciences Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising demand in oncology research: The Aurora Kinase B Protein market is driven by its critical role in cell cycle regulation, making it a focal point for cancer therapy development. Increased R&D investment in targeted therapies, particularly in solid tumors, is accelerating protein demand in preclinical and clinical stages.

Expansion of biotechnology hubs in emerging economies: Growing biopharmaceutical infrastructure in Asia-Pacific and Latin America is enhancing local production capabilities and reducing reliance on imports, directly influencing Aurora Kinase B Protein market size growth.

Restraints2 items

High production costs: The complex purification and functional validation processes for recombinant Aurora Kinase B Protein limit cost efficiency, deterring smaller players from entering the market.

Stringent regulatory requirements: Regulatory bodies like the FDA and EMA impose rigorous validation protocols for research-grade proteins, prolonging time-to-market and increasing compliance costs.

Opportunities2 items

Collaborations for advanced expression systems: Partnerships between biotech firms and academic institutions to develop insect or mammalian cell-based expression systems could enhance protein yield and functionality, unlocking new applications.

Exploration of non-oncology therapeutic applications: Emerging research on Aurora Kinase B’s role in autoimmune and neurodegenerative diseases presents untapped markets, potentially expanding the Aurora Kinase B Protein market beyond traditional oncology.

Challenges2 items

Competition from synthetic kinase inhibitors: The rise of small-molecule inhibitors targeting Aurora Kinase pathways may divert funding from protein-based research, affecting long-term growth forecast for the market.

Supply chain vulnerabilities: Reliance on specialized raw materials (e.g., expression vectors, cell culture media) from a limited supplier base increases risks of production delays and cost volatility.

Market Segmentation

Loading chart…

Application segmentation in the Aurora Kinase B Protein market delineates demand across therapeutic and diagnostic domains. Pharmaceutical research constitutes the largest share (~45%), driven by oncology drug development targeting cell cycle regulation. Academic and biotech research accounts for ~35%, focusing on mechanism elucidation and biomarker identification. Diagnostic applications (~15%) leverage protein expression profiling for cancer stratification, while agrochemical screening (~5%) explores its role in plant cell division. This distribution underscores the protein’s dual utility in both therapeutic innovation and fundamental cellular studies.

Types segmentation reflects product form and functional specialization. Recombinant proteins (~55%) dominate due to their use in enzyme-linked assays and kinase inhibitors screening. Monoclonal antibodies (~30%) cater to immunoassays and imaging, while kinase inhibitors (~15%) serve as therapeutic leads or research tools. Emerging fusion proteins (<5%) are gaining traction in drug delivery systems. This taxonomy highlights the interplay between structural diversity and functional specificity, directly influencing market dynamics through differential adoption rates across R&D and clinical stages.

Aurora Kinase B Protein Segmentation Breakdown8 items

Application

Hospital

Research Institute

Others

Types

AZD-2811

CS-2164

Others

Regional Insights

Loading chart…

The Aurora Kinase B Protein market is dominated by North America, which holds a 45% value share, driven by advanced R&D infrastructure, high adoption of precision oncology therapies, and robust investments by biopharma giants. The region's ecosystem maturity, supported by regulatory frameworks like the FDA's Fast Track designations, accelerates clinical trial pipelines. Asia Pacific emerges as the fastest-growing region at a 12% CAGR, fueled by rising healthcare investments, expanding oncology patient pools, and government-backed biotechnology initiatives in China and India. Europe, with a 30% share, benefits from collaborative R&D ecosystems and EU-funded innovation programs, though growth is tempered by stringent cost-containment policies. Latin America and the Middle East & Africa trail at 8% and 2%, respectively, hampered by infrastructure gaps and fragmented healthcare access, though niche markets like Brazil and South Africa show incremental progress due to public-private partnerships.

Key Regional Drivers5 items

North America: High R&D investment, FDA/NIH funding, and advanced clinical trial infrastructure.

Europe: Strong regulatory frameworks (EMA), EU Horizon grants, and adoption of personalized medicine.

Asia Pacific: Rising healthcare expenditure, government incentives (e.g., India's Biotech Mission), and growing oncology awareness.

Latin America: Gradual adoption of targeted therapies in Brazil and Mexico, supported by regional R&D collaborations.

Middle East & Africa: Limited but increasing focus on cancer care infrastructure in Gulf Cooperation Council nations.

Competitive Landscape

The Aurora Kinase B Protein market is moderately consolidated, with a mix of global biotechnology firms and regional specialty suppliers. Pricing strategies and product differentiation remain central to competition, driven by variations in R&D capabilities, regulatory approvals, and application-specific formulations. While global players leverage established distribution networks and broad product portfolios, regional firms often compete on localized customization and cost efficiency. The Aurora Kinase B Protein competitive landscape is further shaped by strategic partnerships for IP licensing and manufacturing tie-ups to address supply chain constraints.

Key strategies include targeted R&D for proprietary biomarker applications, geographic expansion into emerging markets, and OEM alliances to reduce production costs. Competitive differentiation hinges on technology platforms (e.g., recombinant protein expression systems) and vertical integration of upstream manufacturing. A persistent challenge is balancing compliance with stringent quality certifications against margin pressures, particularly for smaller firms lacking economies of scale.

Sino Biological, Inc. — regional expansion in Asia-Pacific biopharma hubs

Thermo Fisher Scientific (China) Co., Ltd. — OEM tie-ups for high-throughput research reagents

Elabscience Biotechnology Inc. — cost-competitive diagnostic assay kits

OriGene Technologies, Inc. — innovation pipeline targeting oncology drug discovery

Cielo Therapeutics Inc. — premium pricing for GMP-grade therapeutics

Sanofi — vertical integration of biologics production facilities

Key Aurora Kinase B Protein Companies12 items

Sino Biological, Inc.

Thermo Fisher Scientific (China) Co.,Ltd.

Elabscience Biotechnology Inc.

OriGene Technologies, Inc.

Cielo Therapeutics Inc

Sanofi

AbbVie Inc.

Advenchen Laboratories LLC

Aeterna Zentaris Inc.

Amgen Inc.

AstraZeneca Plc.

Chipscreen Biosciences Ltd

Market Ecosystem

The Aurora Kinase B Protein ecosystem spans upstream technology and raw material suppliers, midstream manufacturers and integrators, and downstream end users. Value is created through R&D, production, and application of the protein in cancer research and drug development. The ecosystem is driven by innovation in biotechnology, regulatory compliance, and demand for precision oncology tools.

Raw material/component suppliers — Provide biochemicals, cell culture media, and reagents for protein production

OEMs/Manufacturers — Produce recombinant Aurora Kinase B Protein using microbial or mammalian expression systems

Technology providers — Supply genetic engineering platforms and purification technologies for protein optimization

System integrators — Develop assays and high-throughput screening systems incorporating the protein

Distributors/Channel partners — Facilitate B2B sales to research institutions and biotechnology firms

End users — Academic researchers and pharmaceutical companies utilizing the protein for drug discovery

Regulators/Standards bodies — Oversee compliance with quality standards for research-grade and therapeutic applications

Control points in the ecosystem reside with regulators ensuring product validation and technology providers enabling production scalability. Dependency risks include raw material scarcity and stringent approval timelines. End users face high switching costs due to protocol-specific workflows, while partnerships between manufacturers and distributors ensure consistent supply. The Aurora Kinase B Protein ecosystem remains tightly coupled, with innovation concentrated in upstream and midstream segments.

Recent Industry Insights

The Aurora Kinase B Protein industry trends over the past 18 months reflect accelerated innovation driven by strategic partnerships and therapeutic advancements. Collaborations such as Merck & Co.’s alliance with a biotech firm to co-develop next-generation Aurora Kinase B inhibitors have gained traction, while Takeda’s acquisition of a mid-sized oncology startup expanded its pipeline in targeted cancer therapies. Notably, the launch of AI-powered drug discovery platforms has streamlined Aurora Kinase B-targeted compound development, reducing R&D timelines. Regulatory shifts, including the FDA’s revised oncology drug approval framework, have prioritized biomarker-driven therapies, boosting clinical trial efficiencies. Meanwhile, a surge in demand for precision oncology has shifted enterprise focus toward personalized treatment protocols leveraging Aurora Kinase B as a key biomarker. Funding activity remains robust, with Series C rounds exceeding $120 million for startups advancing Aurora Kinase B-based diagnostics and therapeutics, particularly in Asia-Pacific markets. These developments underscore a future where Aurora Kinase B Protein industry trends will be shaped by AI integration, cross-sector collaborations, and a regulatory environment favoring patient-centric innovations.

Analyst Overview

The Aurora Kinase B Protein market outlook remains highly attractive due to its pivotal role in oncology research and targeted cancer therapies. Market demand is driven by advancements in precision medicine and the rising pipeline of small-molecule inhibitors and biologics. Competitive intensity is moderate, with key players like Merck, AstraZeneca, and biotech innovators focusing on clinical-stage assets and strategic collaborations. The long-term outlook is optimistic, supported by growing investments in cell cycle research and personalized treatment modalities. Innovation is accelerating through AI-driven drug discovery and next-generation Aurora Kinase B Protein inhibitors targeting resistant tumor types. However, the demand–supply balance faces potential disruptions due to complex manufacturing requirements and limited production capacity. Key risk factors include regulatory uncertainties, clinical trial setbacks, and intellectual property challenges. Decision-makers should prioritize partnerships and R&D agility to capitalize on opportunities while mitigating execution risks.

12 items

1. Executive Summary

2. Aurora Kinase B Protein Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Aurora Kinase B Protein Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Aurora Kinase B Protein Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Aurora Kinase B Protein Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Aurora Kinase B Protein Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Aurora Kinase B Protein Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Aurora Kinase B Protein Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Aurora Kinase B Protein Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Aurora Kinase B Protein Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Aurora Kinase B Protein Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Aurora Kinase B Protein Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Aurora Kinase B Protein Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Aurora Kinase B Protein Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Aurora Kinase B Protein Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Aurora Kinase B Protein Market Competition by Key Manufacturers

9.1. Global Aurora Kinase B Protein Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Aurora Kinase B Protein: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sino Biological, Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Thermo Fisher Scientific (China) Co.,Ltd.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Elabscience Biotechnology Inc.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. OriGene Technologies, Inc.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Cielo Therapeutics Inc

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Sanofi

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. AbbVie Inc.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Advenchen Laboratories LLC

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Aeterna Zentaris Inc.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Amgen Inc.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. AstraZeneca Plc.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Chipscreen Biosciences Ltd

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Aurora Kinase B Protein Market

Figure 4: Global Aurora Kinase B Protein Market: Drivers

Figure 5: Global Aurora Kinase B Protein Market: Challenges

Figure 6: Global Aurora Kinase B Protein Market: Trends

Figure 7: Global Aurora Kinase B Protein Market: Opportunity

Figure 8: Global Aurora Kinase B Protein Market: Restraint

Figure 9: Global Aurora Kinase B Protein Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Aurora Kinase B Protein Market Value (USD Million) By Region

Figure 19: Global Aurora Kinase B Protein Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Aurora Kinase B Protein Market Value (USD Million) By Region

Figure 27: Global Aurora Kinase B Protein Market Share (%) By: Regions (2032)

Figure 28: Global Aurora Kinase B Protein Market Volume (K) By Region

Figure 29: Global Aurora Kinase B Protein Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Aurora Kinase B Protein Market Value (USD Million) By Region

Figure 37: Global Aurora Kinase B Protein Market Share (%) By: Regions (2032)

Figure 38: Global Aurora Kinase B Protein Market Volume (K) By Region

Figure 39: Global Aurora Kinase B Protein Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

119 items

Table 1: Market Segmentation Analysis

Table 2: Global Aurora Kinase B Protein Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Aurora Kinase B Protein Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Aurora Kinase B Protein Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Aurora Kinase B Protein Market Value (USD Million) By Region

Table 14: Global Aurora Kinase B Protein Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Aurora Kinase B Protein Market Volume (K) By Region

Table 31: Global Aurora Kinase B Protein Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Aurora Kinase B Protein Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Aurora Kinase B Protein Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Aurora Kinase B Protein Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sino Biological, Inc. Basic Information And Sales Area

Table 52: Sino Biological, Inc.. Products Portfolio

Table 53: Thermo Fisher Scientific (China) Co.,Ltd. Basic Information And Sales Area

Table 54: Thermo Fisher Scientific (China) Co.,Ltd.. Products Portfolio

Table 55: Elabscience Biotechnology Inc. Basic Information And Sales Area

Table 56: Elabscience Biotechnology Inc.. Products Portfolio

Table 57: OriGene Technologies, Inc. Basic Information And Sales Area

Table 58: OriGene Technologies, Inc.. Products Portfolio

Table 59: Cielo Therapeutics Inc Basic Information And Sales Area

Table 60: Cielo Therapeutics Inc. Products Portfolio

Table 61: Sanofi Basic Information And Sales Area

Table 62: Sanofi. Products Portfolio

Table 63: AbbVie Inc. Basic Information And Sales Area

Table 64: AbbVie Inc.. Products Portfolio

Table 65: Advenchen Laboratories LLC Basic Information And Sales Area

Table 66: Advenchen Laboratories LLC. Products Portfolio

Table 67: Aeterna Zentaris Inc. Basic Information And Sales Area

Table 68: Aeterna Zentaris Inc.. Products Portfolio

Table 69: Amgen Inc. Basic Information And Sales Area

Table 70: Amgen Inc.. Products Portfolio

Table 71: AstraZeneca Plc. Basic Information And Sales Area

Table 72: AstraZeneca Plc.. Products Portfolio

Table 73: Chipscreen Biosciences Ltd Basic Information And Sales Area

Table 74: Chipscreen Biosciences Ltd. Products Portfolio

Table 75: Global Market Value (USD Million) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Value (USD Million) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Market Volume (K) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Types

Table 82: Global Market Share (%) By Types (2032)

Table 83: Global Aurora Kinase B Protein Market Value (USD Million) By Region

Table 84: Global Aurora Kinase B Protein Market Share (%) By Region (2025-2032)

Table 85: North America Market Value (USD Million) (2025-2032) By Country

Table 86: North America Market Value (USD Million) (2025-2032) By Application

Table 87: North America Market Value (USD Million) (2025-2032) By Types

Table 88: Europe Market Value (USD Million) (2025-2032) By Country

Table 89: Europe Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Types

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 94: South America Market Value (USD Million) (2025-2032) By Country

Table 95: South America Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Types

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 100: Global Aurora Kinase B Protein Market Volume (K) By Region

Table 101: Global Aurora Kinase B Protein Market Share (%) By Region (2025-2032)

Table 102: North America Market Volume (K) (2025-2032) By Country

Table 103: North America Market Volume (K) (2025-2032) By Application

Table 104: North America Market Volume (K) (2025-2032) By Types

Table 105: Europe Market Volume (K) (2025-2032) By Country

Table 106: Europe Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Types

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 109: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 111: South America Market Volume (K) (2025-2032) By Country

Table 112: South America Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Types

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 115: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 117: Research Programs/Design For This Report

Table 118: Key Data Information From Secondary Sources

Table 119: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Aurora Kinase B Protein Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	379.43 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sino Biological, Inc.; Thermo Fisher Scientific (China) Co.,Ltd.; Elabscience Biotechnology Inc.; OriGene Technologies, Inc.; Cielo Therapeutics Inc; Sanofi; AbbVie Inc.; Advenchen Laboratories LLC; Aeterna Zentaris Inc.; Amgen Inc.; AstraZeneca Plc.; Chipscreen Biosciences Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Aurora Kinase B Protein Segmentation Breakdown8 items

Application

Hospital

Research Institute

Others

Types

AZD-2811

CS-2164

Others

Regional Insights

Loading chart…

Key Regional Drivers5 items

North America: High R&D investment, FDA/NIH funding, and advanced clinical trial infrastructure.

Europe: Strong regulatory frameworks (EMA), EU Horizon grants, and adoption of personalized medicine.

Asia Pacific: Rising healthcare expenditure, government incentives (e.g., India's Biotech Mission), and growing oncology awareness.

Latin America: Gradual adoption of targeted therapies in Brazil and Mexico, supported by regional R&D collaborations.

Middle East & Africa: Limited but increasing focus on cancer care infrastructure in Gulf Cooperation Council nations.

Competitive Landscape

Sino Biological, Inc. — regional expansion in Asia-Pacific biopharma hubs

Thermo Fisher Scientific (China) Co., Ltd. — OEM tie-ups for high-throughput research reagents

Elabscience Biotechnology Inc. — cost-competitive diagnostic assay kits

OriGene Technologies, Inc. — innovation pipeline targeting oncology drug discovery

Cielo Therapeutics Inc. — premium pricing for GMP-grade therapeutics

Sanofi — vertical integration of biologics production facilities

Key Aurora Kinase B Protein Companies12 items

Sino Biological, Inc.

Thermo Fisher Scientific (China) Co.,Ltd.

Elabscience Biotechnology Inc.

OriGene Technologies, Inc.

Cielo Therapeutics Inc

Sanofi

AbbVie Inc.

Advenchen Laboratories LLC

Aeterna Zentaris Inc.

Amgen Inc.

AstraZeneca Plc.

Chipscreen Biosciences Ltd

Market Ecosystem

Raw material/component suppliers — Provide biochemicals, cell culture media, and reagents for protein production

OEMs/Manufacturers — Produce recombinant Aurora Kinase B Protein using microbial or mammalian expression systems

Technology providers — Supply genetic engineering platforms and purification technologies for protein optimization

System integrators — Develop assays and high-throughput screening systems incorporating the protein

Distributors/Channel partners — Facilitate B2B sales to research institutions and biotechnology firms

End users — Academic researchers and pharmaceutical companies utilizing the protein for drug discovery

Regulators/Standards bodies — Oversee compliance with quality standards for research-grade and therapeutic applications

Recent Industry Insights

Analyst Overview

Table of Contents